A Study to Assess if Mirikizumab is Effective and Safe Compared to Secukinumab and Placebo in Moderate to Severe Plaque Psoriasis (OASIS-2)

The reason for this study is to see how effective and safe mirikizumab is compared to secukinumab and placebo for moderate to severe plaque psoriasis.

Trial Summary

Age Range
≥18 years
Conditions the trial is for
Psoriasis
What the trial is testing?
Mirikizumab, Secukinumab
Could I receive a Placebo?
Yes
Enrollment Goal
1484
Trial Dates
Jun 26, 2018 - Jun 3, 2020
How long will I be in the trial?
The study will last about 56 weeks with 12 week follow-up and may include up to 20 visits.
Trial Phase
III

Key Requirements

Clinical trials have inclusion and exclusion requirements to determine which individuals qualify for participation. Listed below are key requirements for this clinical trial, but there may be additional requirements to qualify.

Participants Must:

  • Participant must have chronic plaque psoriasis for at least 6 months

Participants Must Not:

  • Participant must not be breastfeeding or nursing

  • Participant must not have had serious or chronic/recurring infection within 3 months

  • Participant must not have any other skin conditions (excluding psoriasis)

  • Participant must not have previous exposure to Cosentyx, Taltz, Stelara, or similar medications

Lilly Trial Alerts

Not the right fit? Sign up to receive updates about new trials that are listed or when a new trial site begins enrolling near you.